Pharmaceutical compositions

Abstract

Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

What is claimed is: 
     
         1 . A method for treating pain, the method comprising orally administering to a subject in need thereof:
 a) first solid matrix, wherein the first solid matrix comprises an effective amount of a first pharmaceutically active agent for treating or preventing pain in a subject in need thereof, wherein the first pharmaceutically active agent comprises a triptan, and wherein the triptan comprises naratriptan, almotriptan, sumatriptan, zolmitriptan, eletriptan, frovatriptan, or rizatriptan; and   b) a second solid matrix, wherein the solid second matrix comprises an effective amount of promethazine or a pharmaceutically acceptable salt thereof for preventing or reducing nausea or vomiting, and wherein the second matrix is an immediate release matrix.   
     
     
         2 . The method of  claim 1 , wherein the pain is a headache. 
     
     
         3 . The method of  claim 2 , wherein the headache is a migraine headache or a cluster headache. 
     
     
         4 . The method of  claim 2 , wherein the headache is a migraine headache with or without an aura. 
     
     
         5 . The method of  claim 2 , wherein the headache is acute. 
     
     
         6 . (canceled) 
     
     
         7 . The method of  claim 1 , wherein the promethazine or the pharmaceutically acceptable salt thereof is present in an amount of 0.5 mg to 60 mg. 
     
     
         8 . The method of  claim 1 , wherein the promethazine or the pharmaceutically acceptable salt thereof is present in an amount of about 44 mg. 
     
     
         9 . The method of  claim 1 , wherein the pharmaceutically acceptable salt of the promethazine is promethazine hydrochloride. 
     
     
         10 . The method of  claim 9 , wherein the promethazine hydrochloride is present in an amount of about 25 mg or about 50 mg. 
     
     
         11 . The method of  claim 1 , wherein the first solid matrix is in the form of beads, spheres, or pellets, or wherein the second solid matrix is in the form of beads, spheres, or pellets. 
     
     
         12 . The method of  claim 1 , wherein administration of the second solid matrix is prior to administration of the first solid matrix. 
     
     
         13 . A method for treating pain, the method comprising orally administering to a subject in need thereof:
 a) a first solid matrix, wherein the first solid matrix comprises an effective amount of a first pharmaceutically active agent for treating or preventing pain in a subject in need thereof, wherein the first pharmaceutically active agent comprises:
 i) an ergot, and wherein the ergot comprises ergotamine, methysergide, or zonisamide; 
 ii) a beta blocker, wherein the beta blocker comprises acebutolol, arotinolol, atenolol, betaxolol, bisoprolol, butoxamine, carvedilol, carteolol, esmolol, carteolol, carvedilol, labetalol, levobunolol, mepindolol, metoprolol, nebivolol, nadolol, oxprenolol, penbutolol, propranolol, pindolol, sotalol, or timolol; or 
 iii) a calcitonin-gene-related peptide (CGRP) receptor antagonist, and wherein the CGRP receptor antagonist comprises MK-0974, CGRP8-37, BIBN 4096 BS, quinine, nitrobenzamide, 4-oxobutanamide, a cyclopropane derivative, or a benzimidazolinyl piperidine; and 
   b) a second solid matrix, wherein the solid second matrix comprises an effective amount of promethazine or a pharmaceutically acceptable salt thereof for preventing or reducing nausea or vomiting, and wherein the second matrix is an immediate release matrix.   
     
     
         14 . The method of  claim 13 , wherein the pain is a headache. 
     
     
         15 . The method of  claim 14 , wherein the headache is a migraine headache or a cluster headache. 
     
     
         16 . (canceled) 
     
     
         17 . The method of  claim 13 , wherein the promethazine or the pharmaceutically acceptable salt thereof is present in an amount of 0.5 mg to 60 mg. 
     
     
         18 . The method of  claim 13 , wherein the pharmaceutically acceptable salt of the promethazine is promethazine hydrochloride. 
     
     
         19 . The method of  claim 18 , wherein the first solid matrix is in the form of beads, spheres, or pellets, or wherein the second solid matrix is in the form of beads, spheres, or pellets. 
     
     
         20 . The method of  claim 18 , wherein administration of the second solid matrix is prior to administration of the first solid matrix. 
     
     
         21 . The method of  claim 1 , wherein the triptan comprises the sumatriptan. 
     
     
         22 . The method of  claim 1 , wherein the triptan comprises the rizatriptan.